RxDoctor Payments Data

Steven Graeca, DO

Internal Medicine · du Bois, PANPI 1295765030

Payments from drug & device makers

$5,185in general payments, 2019–2025

Across 268 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$918
  • Amgen$594
  • AbbVie$482
  • Johnson & Johnson$389
  • Novo Nordisk$335
  • AstraZeneca$292
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,46986%
  • Education$71714%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,185 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$223,499
Medicare patients
1,087
Services billed
2,906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban745$234,907
JardianceEmpagliflozin166$69,713
EntrestoSacubitril/Valsartan129$52,370
XareltoRivaroxaban178$42,729
OzempicSemaglutide30$38,475
TrulicityDulaglutide33$35,352
RexultiBrexpiprazole73$34,932
FarxigaDapagliflozin Propanediol109$34,878
JanuviaSitagliptin Phosphate71$29,381
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$26,155
MyrbetriqMirabegron102$25,924
Potassium Chloride408$19,567
ProcritEpoetin Alfa22$19,045
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog51$17,612
Dalfampridine ErDalfampridine14$17,368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$91$234,907745 claims
Boehringer IngelheimJardiance, Tradjenta$43$78,397185 claims
Johnson & JohnsonXarelto, Procrit$389$61,774200 claims
NovartisEntresto$108$52,370129 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$156$50,32694 claims
Novo NordiskOzempic, Fiasp$335$43,12445 claims
Lilly USA, LLCTrulicity$178$35,35233 claims
Otsuka America Pharmaceutical, Inc.Rexulti$75$34,93273 claims
AstraZenecaFarxiga$292$34,878109 claims
MerckJanuvia$82$29,38171 claims
Astellas Pharma US IncMyrbetriq$918$25,924102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in du Bois

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →